-
01
2024
2024.01.23 -
Caliway Received First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction
Australian Bellberry HREC has approved Caliway’s application to initiate CBL-514’s Pivotal Phase 3 study (CBL-0301 Phase 3) for subcutaneous fat reduction.
-
01
2024
2024.01.07 -
Caliway Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to treat Dercum’s Disease
Caliway announced that the U.S. FDA has accepted the CBL-514 IND application of CBL-0202 DD Phase 2 Study to treat Dercum’s Disease.
